Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Calando Pharmaceuticals, a majority owned subsidiary of Arrowhead Research Corporation, has announced the issuance of Chinese patent for therapeutic use of RNA interference.
Subscribe to our email newsletter
The Chinese patent broadly covers all methods of using any RNA interference (‘RNAi’) construct formulated in a supramolecular complex to attenuate the expression of any target gene. Supramolecular complex formulations are any that are formed with any type of polymer.
The patent also broadly covers all pharmaceutical compositions of matter containing RNAi constructs adapted for pulmonary or nasal delivery to the lungs. The Chinese patent, with respect to respiratory pharmaceuticals, is not limited to any specific mode of siRNA delivery and provides a basis for delivery of RNAi-based drugs in Chinese patients.
Calando’s CALAA-01 has been cleared by the FDA to begin Phase I clinical trials and is on track to be the first clinical study using targeted, systemic delivery of siRNA and the first siRNA trial in oncology.